Vasculitis & polymyalgia rheumatica
Multicentre case-control study evaluating the safety of anti-SARS-CoV-2 vaccines in a cohort of patients with systemic vasculitis
Authors' conclusion
These data suggest a good risk profile for anti-SARS-CoV-2 vaccine in patients with systemic vasculitis.
Study context
- Population
- Patients with systemic vasculitis and healthy controls from two Italian rheumatology centres, after anti-SARS-CoV-2 vaccination57 ANCA-associated systemic vasculitis (SV)
- Participants
- 107 vs 107
- Comparison
- Patients with systemic vasculitis vs healthy controls after anti-SARS-CoV-2 vaccination
- SVn = 107
- Healthy controls (HC)n = 107reference
- Outcome
- Disease flare (new onset of vasculitis-related clinical manifestations needing an implementation of therapy) and local/systemic AEs after anti-SARS-CoV-2 vaccination
Methodological detailsmulticentre, questionnaire-based
- Multicentre
- Questionnaire-based
Main finding
As reported in the abstract
Disease flare after anti-SARS-CoV-2 vaccination
Disease flare in only one patient (MPA), after the first dose of an mRNA vaccine
0.93%
Observational data: associations, not effects.
Safety
AEs after first and second vaccine dose
- No significant differences in AEs between SV and HC
Serious AEs
- No serious AEs were reported
Original publication
Multicentre case-control study evaluating the safety of anti-SARS-CoV-2 vaccines in a cohort of patients with systemic vasculitis. Clin Exp Rheumatol. Published 18 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →